Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2025

SELL
N/A
-7,500 Closed
0 $0
Q1 2023

Feb 12, 2025

SELL
$21.53 - $26.8 $116,262 - $144,720
-5,400 Reduced 41.86%
7,500 $174 Million
Q4 2022

Feb 12, 2025

BUY
$18.63 - $27.35 $240,327 - $352,815
12,900 New
12,900 $338 Million

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Bit Capital Gmb H Portfolio

Follow Bit Capital Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bit Capital Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Bit Capital Gmb H with notifications on news.